ClinicalTrials.gg
RecruitingNCT07559474Updated Jun 16, 2026

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

A Phase 1 interventional study of INCB123667 in Hepatic Insufficiency and Liver Diseases, sponsored by Incyte Corporation. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Hepatic Insufficiency with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Hepatic Insufficiency · United States.

Planned enrollment
38th of 48
16 · median 28
Started
2026
with 2 others
Phase 1
42 of 52
3 open now
Registered
51st of 52
by date

Among the 52 studies in Hepatic Insufficiency with a site in United States, this one is the 38th largest by planned enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2026, is one of 42 in phase 1, and was the 51st registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

3 of the 52 studies in Hepatic Insufficiency with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Hepatic Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with moderate or severe hepatic impairment.

03

Conditions studied

  • Hepatic Insufficiency
  • Liver Diseases

Keywords

  • hepatic impairment
  • liver impairment (moderate and severe)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to comprehend and willingness to sign a written ICF for the study.
  • Aged 18 to 80 years, inclusive, at the time of signing the ICF.
  • Moderate or severe hepatic impairment based on CP score.
  • Medical findings consistent with the degree of hepatic dysfunction, determined by medical history, physical examination, vital sign measurements, 12-lead ECGs, and clinical laboratory determinations at screening or check-in (as applicable). Participants with abnormal findings considered not by the medical monitor or investigator are eligible.
  • of 18.0 to 43.0 kg/m2 (inclusive).
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • Participants who have a current, functioning organ transplant or are on the national transplant list and expected to receive a transplant within 3 months.
  • Tobacco or nicotine-containing product use of > 10 cigarettes per day within 1 month before screening.
  • Participants who had a change in disease status within 30 days before screening, as documented by the participant's medical history, that is deemed by the investigator.
  • Participants who have a history of paracentesis within 2 months prior to check-in.
  • Participants who required new medication or an increase in dose for hepatic encephalopathy within 3 months prior to check-in.
  • Participants who have a history of unstable diabetes mellitus (as evidenced by ≥ 10.0%). Medications for treatment of diabetes mellitus must be reviewed and approved by the investigator and medical monitor. Participants who have a portal systemic shunt. Up to 3 participants with transjugular intrahepatic portosystemic shunt may be included.
  • Participants who had esophageal banding within 3 months prior to check-in or required any other treatment for gastrointestinal bleeding within 6 months prior to check-in.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Moderate hepatic function

    Participants with moderate hepatic impairment will be enrolled in Cohort 1.

    Drug: INCB123667

  • Experimental
    Cohort 2: Severe hepatic function

    Participants with severe hepatic impairment will be enrolled in Cohort 2.

    Drug: INCB123667

Interventions

06

What researchers measure

Primary outcomes

  1. PK for plasma INCB123667: Cmax

    Defined as the maximum plasma concentration.

    Time frame: Up to approximately 2 months

  2. PK for plasma INCB123667: AUCt

    Defined as area under the concentration-time curve from time zero to time of last quantifiable concentration.

    Time frame: Up to approximately 2 months

  3. PK for plasma INCB123667: AUC∞

    Defined as area under the single-dose concentration-time curve extrapolated to time of infinity.

    Time frame: Up to approximately 2 months

Secondary outcomes

  1. Number of Treatment-Emergent Adverse Events (TEAEs)

    Adverse events reported for the first time or worsening of a pre-existing event, occurring after study drug/treatment.

    Time frame: Up to approximately 2.5 months

07

Study locations

4 of 4 sites recruiting
  • Arizona Clinical Trials - the Institute For Liver Health
    Chandler, Arizona 85225, United States
    Recruiting
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
    Recruiting
  • Texas Liver Institute - American Research Corporation
    San Antonio, Texas 78215, United States
    Recruiting
  • Pinnacle Clinical Research
    San Antonio, Texas 78229, United States
    Recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Apr 2027, 10 months after the start.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's planned 10 months is above that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
Apr 30, 2026
StartActual
May 27, 2026
Primary completionEst.
Apr 13, 2027
CompletionEst.
Apr 13, 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07559474
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
May 27, 2026
Primary completion
Apr 13, 2027 (estimated)
Completion
Apr 13, 2027 (estimated)
Last update
Jun 16, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423
Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CDK2 Inhibitor INCB123667

Start the discussion